Markets:

Overview

News

Currencies

International

Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

218.62 +1.24 (+0.57%)

Streaming Delayed Price Updated: 12:40 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum ↗

January 28, 2026

Via Chartmill

Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan ↗

December 25, 2025

Ascendis Pharma (ASND) meets Mark Minervini's strict criteria, showing a powerful technical uptrend paired with explosive revenue growth over 269%.

Via Chartmill

Why Dyne Therapeutics Stock Was Crushing it This Week ↗

November 21, 2025

The company has solid potential with its development of drugs targeting muscle disorders.

Via The Motley Fool

Topics Artificial Intelligence

European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility

November 19, 2025

European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

A Look Ahead: Ascendis Pharma's Earnings Forecast ↗

November 11, 2025

Via Benzinga

How Do Investors Really Feel About Ascendis Pharma? ↗

August 28, 2025

Via Benzinga

Ascendis (ASND) Q3 2025 Earnings Call Transcript ↗

November 13, 2025

Ascendis (ASND) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

November 12, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗

October 29, 2025

Via Benzinga

Looking Into Ascendis Pharma AS's Recent Short Interest ↗

October 21, 2025

Via Benzinga

Ascendis Pharma A/S - ADR (NASDAQ:ASND) Shows Strong Growth Momentum in Technical and Fundamental Analysis ↗

October 14, 2025

Ascendis Pharma (ASND) is a high-growth stock with strong technical uptrends and impressive fundamentals, including surging revenue and earnings momentum.

Via Chartmill

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Peering Into Ascendis Pharma's Recent Short Interest ↗

July 03, 2025

Via Benzinga

Is Ascendis Pharma Gaining or Losing Market Support? ↗

June 03, 2025

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗

May 29, 2025

Via Benzinga

What Does the Market Think About Ascendis Pharma AS? ↗

September 29, 2025

Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has fallen 14.63% since its last report. According to exchange reported data, there are now 2.29 million shares sold short, which...

Via Benzinga

$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗

September 25, 2025

Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 13.64% on an annualized basis producing an average annual return of 26.77%. Currently, Ascendis Pharma has a market...

Via Benzinga

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗

September 08, 2025

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study.

Via Benzinga

$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗

September 08, 2025

Via Benzinga

Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗

September 04, 2025

Via Benzinga

ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Technical Strength and High-Growth Momentum ↗

September 01, 2025

Ascendis Pharma (ASND) excels in both technical & fundamental momentum, meeting Minervini's Trend Template criteria for high-growth stocks poised for potential outperformance.

Via Chartmill

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗

August 19, 2025

Via Benzinga

Ascendis (ASND) Q2 2025 Earnings Call Transcript ↗

August 07, 2025

Via The Motley Fool

Topics Earnings

What's Driving the Market Sentiment Around Ascendis Pharma? ↗

August 06, 2025

Via Benzinga

What's Driving the Market Sentiment Around Ascendis Pharma? ↗

August 04, 2025

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

July 28, 2025

Via Benzinga

Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗

July 22, 2025

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

July 07, 2025

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

June 12, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.